ALIGOS Therapeutics

  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers
  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers

Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone

Publication, Publications

Discovery and Preclinical Profile of ALG-055009, a Potent and Selective Thyroid Hormone

Publication, Publications

An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients

Publication, Publications

Synthesis and evaluation of highly potent HBV capsid assembly modulators (CAMs)

Publication, Publications

Tumor Regression upon Intratumoral and Subcutaneous Dosing of the STING Agonist ALG-031048 in Mouse Efficacy Models

Publication, Publications

Class A capsid assembly modulator RG7907 clears HBV-infected hepatocytes through core-dependent hepatocyte death and proliferation

Publication, Publications

Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profiles

Publication, Publications

Establishment of a robust rat hepatitis E virus fecal-oral infection model and validation for antiviral studies

Publication, Publications

The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor In Vitro and Confer Resistance To Nirmatrelvir

Publication, Publications

Nomenclature of HBV core protein-targeting antivirals

Publication, Publications

Opportunities and Challenges in Targeting the Proofreading Activity of SARS-CoV-2 Polymerase Complex

US OFFICE
1 Corporate Dr., 2nd Floor
South San Francisco, CA 94080

EU OFFICE
Gaston Geenslaan 1 / (Building 3)
3001 Leuven, Belgium

CHINA OFFICE
Unit 3212, Building A, No. 100, Zunyi Road, Changning District, Shanghai, People’s Republic of China, 200051

FOLLOW US

info@aligos.com

© Aligos Therapeutics 2025

  • Privacy Policy
  • Terms of Service
MENU
  • About
    • Overview
    • Management
    • Board of Directors
  • Science
    • Pipeline
    • Posters & Presentations
  • Patients
    • Chronic HBV Infection
    • MASH
    • Expanded Access Policy
  • News & Media
    • Press Releases
    • Presentations & Events
  • Investors
    • Overview
    • Stock
      • Stock Quote & Chart
      • Analyst Coverage
    • News & Events
      • News Releases
      • Investor Calendar
    • Financials
      • SEC Filings
      • Quarterly Results
    • Governance
      • Governance Highlights
      • Committee Composition
    • Resources
      • Investor FAQs
      • Email Alerts
      • Contact IR
  • Careers